
Gilead signs generic deals for experimental Ebola drug
The story in brief
Gilead Sciences signed royalty-free deals with three generic drugmakers to make its experimental Ebola prevention drug available in 127 low- and lower-middle-income countries. The drug, obeldesivir, is in trials and not yet approved for any use. Manufacturing is set to begin ahead of trial results and regulatory filings.